205 studies found for:    Primary Lateral Sclerosis
Show Display Options
Rank Status Study
21 Completed Safety Extension Study of TRO19622 in ALS
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: TRO19622
22 Unknown  Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Other: Sleep study-guided adjustment of NIV;   Other: Standard initiation of NIV
23 Terminated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Conditions: Frontotemporal Dementia;   Amyotrophic Lateral Sclerosis
Intervention:
24 Terminated Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: pioglitazone;   Drug: placebo
25 Terminated
Has Results
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Lithium Carbonate;   Drug: Riluzole;   Drug: placebo
26 Recruiting Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Condition: Amyotrophic Lateral Sclerosis
Intervention:
27 Active, not recruiting Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Rasagiline;   Drug: Placebo
28 Completed Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Ozanezumab;   Drug: Placebo
29 Completed Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)
Conditions: Amyotrophic Lateral Sclerosis;   Sialorrhea
Interventions: Drug: Botulinum toxin type B (Myobloc);   Procedure: Injection of salivary glands
30 Completed Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: MCI-186;   Drug: Placebo of MCI-186
31 Completed CARE Canadian ALS Riluzole Evaluation
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: Riluzole
32 Completed Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: NP001;   Drug: Placebo
33 Recruiting Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Interventions: Dietary Supplement: Calogen;   Dietary Supplement: Placebo
34 Unknown  Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis
Conditions: Amyotrophic Lateral Sclerosis;   Chronic Respiratory Failure
Interventions: Device: Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers;   Device: Non invasive ventilation
35 Terminated The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Intervention: Behavioral: Intensive Controlled Exercise
36 Recruiting Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis (ALS)
Intervention: Device: NeuRx® Diaphragm Pacing System™ (DPS)
37 Active, not recruiting Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: MCI-186;   Drug: Placebo;   Drug: MCI-186 in open label phase
38 Completed
Has Results
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: tauroursodeoxycholic acid (TUDCA);   Drug: Placebo
39 Recruiting Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis
Intervention: Biological: Human Neural Stem Cells
40 Not yet recruiting Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase I-II Study of Safety and Activity of Low Dose Interleukin-2
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Placebo;   Drug: 0.5 MIU IL-2 per day;   Drug: 1.0 MIU IL-2 per day;   Drug: 2.0 MIU IL-2 per day

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years